TY - JOUR T1 - Persistent abnormalities on echocardiography post hospitalization for COVID-19 JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.OA86 VL - 58 IS - suppl 65 SP - OA86 AU - Bavithra Vijayakumar AU - James Tonkin AU - Pallav L Shah Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/OA86.abstract N2 - Introduction: Currently there is a paucity of literature on the long-term cardiac sequelae in COVID-19 survivors.Methods: We prospectively reviewed patients discharged post COVID-19, measured cardiac biomarkers (troponin/BNP) and performed an echocardiogram irrespective of symptoms as part of PHENOTYPE (NCT 04459351).Results: 67 echocardiograms were performed between June and December 2020 at an average of 155.2 days (+/- 43.2) from discharge. Mean age was 59.9 (+/-11.8), 45/67 (67.2%) were male, 35/67 (52.2%) from BAME backgrounds and median length of hospital stay was 8 days (3-16.5).Left ventricular (LV) dysfunction was found in 8/67 (11.9%), right ventricular (RV) dysfunction in 4/67 (6.0 %) and a small pericardial effusion in 9/67 (13.4%), none requiring therapeutic intervention. LV dysfunction varied from 39%-54% predicted. Only one patient with LV dysfunction had pre-existing ischaemic heart disease. 4/8 (50%) had required invasive or positive pressure ventilation. 2/4 (50%) with RV dysfunction had acute pulmonary embolism, of which one had features of chronic thrombo-embolic disease at follow up. At least one cardiac abnormality was found in 16/67 (23.9%). 82.3 % of those with cardiac abnormalities reported breathlessness and all except one had parenchymal changes on CT thorax.None of the patients had been diagnosed with cardiac dysfunction during their inpatient stay, all had a normal troponin at follow up and 14/16 had a normal BNP.Discussion: Cardiac abnormalities may exist post COVID-19 and predicting this is challenging. Patient-reported breathlessness and cardiac biomarkers may not be useful in predicting cardiac impairment.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA86.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -